↓ Skip to main content

Assessment of a revolving drug fund for essential asthma medicines in Benin

Overview of attention for article published in Journal of Pharmaceutical Policy and Practice, April 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#26 of 131)
  • Good Attention Score compared to outputs of the same age (78th percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

policy
1 policy source
twitter
5 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
25 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Assessment of a revolving drug fund for essential asthma medicines in Benin
Published in
Journal of Pharmaceutical Policy and Practice, April 2015
DOI 10.1186/s40545-015-0033-7
Pubmed ID
Authors

Gildas Agodokpessi, Nadia Aït-Khaled, Martin Gninafon, Leon Tawo, Wilfried Bekou, Christophe Perrin, Karen Bissell, Nils Billo, Donald A Enarson, Chen-Yuan Chiang

Abstract

Benin established a revolving drug fund (RDF) for essential asthma medicines in 2008. We evaluated the operation of the RDF and assessed whether there was interruption of supply of asthma medicine from 2008 to 2013. We reviewed the process in establishing the RDF. We assessed cost and sale price of asthma medicines, expenditure of the RDF in procuring asthma medicines and other tools, revenue generated by sales of medicines to patients, and balance of capital as of 31 January 2013. We investigated whether there was interruption of supply of essential asthma medicines from 2008-2013. The total amount of grants initially injected into the RDF was 24,101€. As of 31 January 2013, the capital of the RDF, including the deposit in the RDF bank account (8,114€) and the value of inhalers in stock (12,172€), was equivalent to 20,586€, slightly less than the initial capital (24,101€). The decrease of capital was mainly because a number of inhalers were expired or provided free-of-charge (6,091€) and because part of the fund was used to procure other elements required for the management of asthma (4,338€). Thanks to a RDF, Benin maintained an uninterrupted supply of essential asthma medicines in asthma pilot sites from 2008-2013. The Benin experience demonstrated that in countries where universal health coverage was not yet in place, establishment of a RDF may help maintain an uninterrupted supply of essential medicines.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
South Africa 1 4%
Unknown 24 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 24%
Researcher 6 24%
Student > Postgraduate 3 12%
Student > Bachelor 2 8%
Student > Ph. D. Student 1 4%
Other 2 8%
Unknown 5 20%
Readers by discipline Count As %
Medicine and Dentistry 7 28%
Nursing and Health Professions 4 16%
Pharmacology, Toxicology and Pharmaceutical Science 3 12%
Social Sciences 2 8%
Economics, Econometrics and Finance 2 8%
Other 3 12%
Unknown 4 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 January 2017.
All research outputs
#1,453,074
of 8,838,295 outputs
Outputs from Journal of Pharmaceutical Policy and Practice
#26
of 131 outputs
Outputs of similar age
#43,788
of 205,424 outputs
Outputs of similar age from Journal of Pharmaceutical Policy and Practice
#2
of 9 outputs
Altmetric has tracked 8,838,295 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 131 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 205,424 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.